NDC 68071-4963-01 - Hydrochlorothiazide
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68071-4963
- Requested NDC
- 68071-4963-01
- Package NDCs from labels
- 68071-4963-9, 68071-4963-1, 68071-4963-01
- Manufacturer
- NuCare Pharmaceuticals,Inc.
- Effective date
- 2025-06-27
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| HYDROCHLOROTHIAZIDE TABLETS USP 2083 2089 Rx only | NuCare Pharmaceuticals,Inc. | 2025-06-27 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| Effective | Related label |
|---|---|
| 2023-02-02 | HYDROCHLOROTHIAZIDE TABLETS USP 2083 2089 Rx only |
| 2023-01-30 | HYDROCHLOROTHIAZIDE TABLETS USP 2083 2089 Rx only |
| 2021-02-18 | HYDROCHLOROTHIAZIDE TABLETS USP 2083 2089 Rx only |
| 2021-01-29 | HYDROCHLOROTHIAZIDE TABLETS USP 2083 2089 Rx only |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68071-4963-1 | Hydrochlorothiazide | 20 in 1 BOTTLE | TABLET | 20 | 6 | |
| 68071-4963-9 | Hydrochlorothiazide | 90 in 1 BOTTLE | TABLET | 90 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68071-4963 | HYDROCHLOROTHIAZIDE TABLET [NUCARE PHARMACEUTICALS,INC.] | 5 | Current NDC, Legacy NDC, 2 package rows | 20250105_8d5a9196-5f1d-2d83-e053-2a95a90a6036.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Bryant Ranch Prepack | 5de62aee-f3cc-4aaa-8588-2aed2bdeced9 | 2023-11-14 | Warnings, Adverse reactions | 0J48LPH2TH |
| Lisinopril and Hydrochlorothiazide | LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS | Bryant Ranch Prepack | 5885b1ff-715c-4f90-b43d-bddf94d61acd | 2023-11-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | A-S Medication Solutions | 94cd40a1-65bc-4b1b-bb05-cec93bc96502 | 2023-11-01 | Warnings, Adverse reactions | 310798 0J48LPH2TH |
| Lisinopril and Hydrochlorothiazide | LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS | Bryant Ranch Prepack | 1990af86-e9ec-48b8-b354-8456d6d80e0a | 2023-11-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Viona Pharmaceuticals Inc | 9925ab75-e3b7-43b7-888e-a2c8763240ba | 2023-10-31 | Boxed warning, Adverse reactions | 0J48LPH2TH |
| VALSARTAN AND HYDROCHLOROTHIAZIDE | VALSARTAN AND HYDROCHLOROTHIAZIDE | A-S Medication Solutions | 3131809e-885a-42d3-b6ad-1b208fd3ba56 | 2023-10-31 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Valsartan and Hydrochlorothiazide | VALSARTAN AND HYDROCHLOROTHIAZIDE | A-S Medication Solutions | 89ce2fb1-330c-45f9-bd37-b402feea9378 | 2023-10-31 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| triamterene and hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | A-S Medication Solutions | 27b8f965-d73f-411c-aae6-bcae6e281113 | 2023-10-23 | Boxed warning, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | NCS HealthCare of KY, LLC dba Vangard Labs | d6b933c6-f5f8-406a-84d6-b22c6040482a | 2023-10-19 | Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Bryant Ranch Prepack | 24cba606-263f-46dc-a4dc-fddc729c0f4b | 2023-10-18 | Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Proficient Rx LP | 9dd2f58b-d143-4d0c-a298-6d9390e6187a | 2023-10-01 | Warnings, Adverse reactions | 0J48LPH2TH |
| Benazepril Hydrochloride and Hydrochlorothiazide | BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | Glenmark Pharmaceuticals Inc., USA | 51b0aed8-a229-4d2c-8fdf-aa957fddc41b | 2023-09-30 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Olmesartan Medoxomil and Hydrochlorothiazide | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | A-S Medication Solutions | ba452478-f40c-446e-b61d-388379a55efd | 2023-09-18 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Telmisartan and Hydrochlorothiazide | TELMISARTAN AND HYDROCHLOROTHIAZIDE | Alembic Pharmaceuticals Inc. | e80f232c-c1c4-4524-a0a5-d23ee0d1f3b7 | 2023-09-15 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | A-S Medication Solutions | b9e1bed7-fef9-434a-92f9-b70941176e3e | 2023-09-11 | Warnings, Adverse reactions | ANDA083177 310798 0J48LPH2TH |
| triamterene and hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Zydus Lifesciences Limited | 1af80800-e7a5-42e5-aa6c-3f61aff4a77b | 2023-08-31 | Boxed warning, Adverse reactions | 0J48LPH2TH |
| triamterene and hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Zydus Pharmaceuticals (USA) Inc. | fa69eeb8-ec82-4be1-8cb7-f64094ed957c | 2023-08-26 | Boxed warning, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | A-S Medication Solutions | 1bb00980-eeea-4722-b010-e208f3ec2214 | 2023-08-24 | Warnings, Adverse reactions | 310798 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | 8d992a4c-8740-4636-928f-bb808eae3336 | 2023-08-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Benicar HCT | OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE | Cosette Pharmaceuticals, Inc. | 881a1c32-c209-4038-9c5e-c5e46c6e0546 | 2023-07-12 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.